arrow
A

Aleksandr Lazaryan

h lee moffitt cancer center
H指数:36
被引数:5,226

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hematopoietic Cell Transplantation Outcomes in the Era of Post-Transplant Cyclophosphamide: Comprehensive Donor Analysis

移植后环磷酰胺时代的造血细胞移植结局:全面的供者分析

2026-10-230
OA
Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel

年龄作为接受阿西替尼胞苷治疗的大B细胞淋巴瘤患者神经认知表现的调节变量

2026-09-080
OAAI
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma

一种新型无严重毒性、无进展生存期终点的预测指标可预测CD19嵌合抗原受体-T细胞疗法在大型B细胞淋巴瘤中的治疗效果

2026-07-170
OAAI
Transportability to the European Population of Efficacy of Belumosudil as Compared With Physician's Choice of Best Available Therapy for the Treatment of Chronic Graft Versus Host Disease

与医生选择的最佳可用疗法相比,Belumosudil治疗慢性移植物抗宿主病在欧洲人群中有效性的可转移性

2026-06-010
OAAI
Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age

单倍型与匹配无关供者移植联合移植后环磷酰胺:基于平台的机器学习分析供者年龄

Leukemia
IF13.4
2026-04-150
OAAI
Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT)

单中心评估一种复合风险预测模型,用于预测异基因造血细胞移植(HCT)后的非复发死亡率。

2026-04-080
PRE
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

肥胖及基于体重的化疗剂量调整对急性髓系白血病异基因造血细胞移植结局的影响

2025-10-200
PRE
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide

Letermovir可降低接受移植后环磷酰胺治疗的HLA匹配和错配异基因造血细胞移植患者中的巨细胞病毒水平。

2025-07-050
PRE
Role of Donor Cytomegalovirus Serostatus in Cytomegalovirus-Seronegative Recipients of Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis

供者巨细胞病毒血清学状态在采用异基因供者造血细胞移植并接受术后环磷酰胺预防的巨细胞病毒血清学阴性受者中的作用

2025-05-140
PRE
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

静脉免疫球蛋白(IVIG)用于与嵌合抗原受体T细胞(CAR-T)疗法相关的严重神经毒性患者

2025-04-210
OA
Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation

供者年龄和供者巨细胞病毒血清状态对亲属供者异基因造血干细胞移植后结局的影响

2025-03-120
PRE
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
2024-10-011
PRE
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation

HHV-6B再激活的单倍体干细胞移植受者的结果

2024-09-260
OAAI
Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

首次反应的自体造血细胞移植巩固与淋巴结周围T细胞淋巴瘤患者的生存期延长有关

2024-09-010
PRE
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

完全缓解的DLBCL患者的自体移植与car-t治疗

2024-07-081
OAAI
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
2024-03-280
OAAI